ALKEM vs COHANCE: Stock Comparison

Alkem Laboratories Limited vs Cohance Lifesciences Limited

Live data: 22 July 2026, 3:06 PM IST • Source: NSE and company filings

Alkem Laboratories Limited is the larger company by market capitalisation. Alkem Laboratories Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Cohance Lifesciences Limited shows lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Alkem Laboratories Limited and Cohance Lifesciences Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, ALKEM is more favourable on 11 of 13 scored metrics and COHANCE on 2These counts are context-free and are not an overall rating.

Key Differences

Market Cap
ALKEM is the larger company
₹66,765 Cr vs ₹16,741 Cr
P/E Ratio
ALKEM has a lower P/E
29.54x vs 95.36x
P/B Ratio
COHANCE has a lower P/B
4.37x vs 4.92x
EPS
ALKEM has higher earnings per share
₹192.78 vs ₹4.69
Dividend Yield
ALKEM has a higher dividend yield
0.35% vs 0%
Revenue Growth (TTM YoY)
ALKEM has faster revenue growth
14.6% vs -26.3%
EPS Growth (TTM YoY)
ALKEM has faster EPS growth
-22.7% vs -89%
Qtr Sales Growth
ALKEM has stronger quarterly sales growth
14.6% vs -26.3%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricALKEMCOHANCE
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricALKEMCOHANCE
Live Price₹5,585.5₹438
Day Change-1.69%-1.72%
Volume96,7165.06 L
52-Week High₹5,933.5₹1,079
52-Week Low₹4,738.5₹266.7
Distance from 52W High-5.87%-59.41%

Valuation

MetricALKEMCOHANCE
Market Cap₹66,765 Cr₹16,741 Cr
P/E Ratio29.54x95.36x
P/B Ratio4.92x4.37x
EPS₹192.78₹4.69
Book Value₹1,155.47₹102.03
Dividend Yield0.35%0%

Growth

MetricALKEMCOHANCE
Revenue Growth (TTM YoY)14.6%-26.3%
EPS Growth (TTM YoY)-22.7%-89%
Qtr Sales Growth14.6%-26.3%
Qtr Profit Growth2.04%-86.6%

Profitability & Leverage

MetricALKEMCOHANCE
ROE18.9%7.04%
ROCE21.2%8.35%
Net Margin15.65%7.9%
Operating Margin20.4%18.8%
Debt to Equity0.15x0.1x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricALKEMCOHANCE
Promoter Holding49.7% 1.5 pp0%
FII Holding10.42% 0.26 pp6.5% 0.91 pp
DII Holding22.63% 1.23 pp20.09% 1.7 pp
Public Holding17.25%15.92% 0.8 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Alkem Laboratories Limited and Cohance Lifesciences Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.